2008/04/03 by Fernando Flota-Cervera, Cintia Flota-Ruiz, Carlos Treviño +2
Medicine · #Diagnosis and Treatment of Venous Diseases #Lymphatic System and Diseases #Venous Thromboembolism Diagnosis and Management
paper · doi:10.1177/0003319707305407
openalex publication_date 2008/04/03 · crossref created 2008/04/03 · crossref issued 2008/05/13 · crossref published 2008/05/13 · crossref published-online 2008/05/13 · crossref published-print 2008/06/01 · openalex created_date 2025/10/10 · crossref deposited 2026/04/28 · crossref indexed 2026/07/30 · openalex updated_date 2026/07/31
The aims of the present study were to investigate the effect of calcium dobesilate on lymph flow and lymphovenous edema in patients with chronic venous disease. It was a randomized, placebo-controlled, double-blind clinical trial. Patients received 1 capsule of 500 mg calcium dobesilate every 8 hours (1.5 g/day) or placebo by 49 days. By the end of the treatment period, only the patients treated with calcium dobesilate had normalization of lymphogammagraphy (capture index and speed of lymph flow; 80 and 78%, respectively). Only patients treated with calcium dobesilate had statistically significant reduction in the perimeter of leg, calf, and ankle. Twenty-two out of 25 (88%) calcium dobesilate-treated patients presented clinical improvement versus 5 out of 24 (20.8%) in the placebo group. One patient on calcium dobesilate developed rash and one patient on placebo complained of vomiting. In the present study, calcium dobesilate normalized lymph physiology and improved symptoms in patients with chronic venous disease.